Antiestrogens induce transforming growth factor β-mediated immunosuppression in breast cancer

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1314-1322

  Joffroy, Christian M ^a   Buck, Miriam B ^a   Stope, Matthias B ^a   Popp, Simone L ^a   Pfizenmaier, Klaus ^a   Knabbe, Cornelius ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; FAS LIGAND; GRANZYME B; NEUTRALIZING ANTIBODY; PERFORIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL STRAIN MCF 7; CYTOTOXICITY; DOWN REGULATION; EFFECTOR CELL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

EID: 76749135760     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3292     Document Type: Article

References (29)

1. Jordan VC. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993;110:507-17.
2. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331-6S.
3. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001;53:25-71.
4. Buck MB, Knabbe C. TGF-β signaling in breast cancer. Ann N Y Acad Sci 2006;1089:119-26.
5. Dumont N, Arteaga CL. Transforming growth factor-β and breast cancer: tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2000;2:125-32.
6. Oft M, Heider KH, Beug H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998;8:1243-52.
7. Padua D, Massague J. Roles of TGFβ in metastasis. Cell Res 2009; 19:89-102.
8. Janda E, Lehmann K, Killisch I, et al. Ras and TGF[β] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002;156:299-313.
9. de Jong JS, van Diest PJ, van d V, Baak JP. Expression of growth factors, growth factor receptors and apoptosis related proteins in invasive breast cancer: relation to apoptotic rate. Breast Cancer Res Treat 2001;66:201-8.
10. Gajdusek CM, Luo Z, Mayberg MR. Basic fibroblast growth factor and transforming growth factor β-1: synergistic mediators of angiogenesis in vitro. J Cell Physiol 1993;157:133-44.
11. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor typeβ: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986;83:4167-71.
12. Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003;63:1860-4.
13. Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood 2001;98:2992-8.
14. Lee YJ, Han Y, Lu HT, et al. TGF-β suppresses IFN-γ induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol 1997;158:2065-75.
15. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998;64: 275-90.
16. McKarns SC, Schwartz RH, Kaminski NE. Smad3 is essential for TGF-β 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol 2004;172:4275-84.
17. Thomas DA, Massague J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8:369-80.
18. Malygin AM, Meri S, Timonen T. Regulation of natural killer cell activity by transforming growth factor-β and prostaglandin E2. Scand J Immunol 1993;37:71-6.
19. +. J Immunol 2004;172:5149-53.
20. Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 2003;6:169-72.
21. van der Kuip H, Murdter TE, Sonnenberg M, et al. Short term culture of breast cancer tissues to study the activity of the anticancer drug Taxol in an intact tumor environment. BMC Cancer 2006;6:86.
22. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007;123:18-29.
23. Mallmann P, Krebs D. Effect of tamoxifen on parameters of cell-mediated immunity in postmenopausal patients with breast carcinoma. Zentralbl Gynakol 1991;113:689-96.
24. Robinson E, Rubin D, Mekori T, Segal R, Pollack S. In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer. Cancer Immunol Immunother 1993;37:209-12.
25. Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol 2008;21:1527-32.
26. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523-32.
27. + regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol 2009;174:1575-87.
28. Nalbandian G, Paharkova-Vatchkova V, Mao A, Nale S, Kovats S. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol 2005;175:2666-75.
29. Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006;25: 323-31.